NEW YORK (GenomeWeb News) — Becton Dickinson today said that fiscal third-quarter revenues rose 11.6 percent as R&D spending climbed 21 percent and profit grew 19 percent.
Total receipts for the three months ended June 30 increased to $1.63 billion from $1.46 billion year over year.
BD said revenues from its Diagnostics segment grew 15 percent to $492 million, while Biosciences revenue rose 13 percent to $258 million. Revenue from the Medical segment rose 10 percent to $882 million.
R&D spending for the quarter rose to $93 million from $77 million year over year.
Profits for the quarter increased to $245 million from $206 million in the year-ago period.
The company did not disclose its balance sheet for the period.